Sector revisions Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 24/01/2026 am IST			5-day change	1st Jan Change
44.27 ^USD	-0.52%		+0.71%	+1.00%

14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
13/01	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	EXELIXIS, INC.							18
	ARGENX SE							15
	WUXI APPTEC CO., LTD.							18
	INSMED INCORPORATED							19
	BIONTECH SE							19
	WUXI BIOLOGICS (CAYMAN) INC.							25
	GENMAB A/S							13
	SUMMIT THERAPEUTICS INC.							13
	AKESO, INC.							22
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							17
	MADRIGAL PHARMACEUTICALS, INC.							14
	SAMSUNG EPIS HOLDINGS CO., LTD.		-	-	-	-	-	1
	ARROWHEAD PHARMACEUTICALS, INC.							12
	NUVALENT, INC.							17
	CYTOKINETICS, INCORPORATED							18
	REMEGEN CO., LTD.							15
	Average							16
	Weighted average by Cap.							17

Bio Therapeutic Drugs

As early as today, start finding the best investment opportunities!